{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T22:40:35Z","timestamp":1740350435602,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1992,4,1]],"date-time":"1992-04-01T00:00:00Z","timestamp":702086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. J. Drug Metab. Pharmacokinet."],"published-print":{"date-parts":[[1992,4]]},"DOI":"10.1007\/bf03188779","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T02:20:01Z","timestamp":1281061201000},"page":"115-120","source":"Crossref","is-referenced-by-count":16,"title":["In vitro forecasting of drugs that may interfere with codeine bioactivation"],"prefix":"10.1007","volume":"17","author":[{"given":"P.","family":"Dayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Desmeules","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Strffierni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03188779_CR1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0006-291X(88)80729-0","volume":"152","author":"P. Dayer","year":"1988","unstructured":"Dayer P., Desmeules J., Leemann T., Stribemi R. (1988): Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation. Biochem. Biophys. Res. Commun., 152, 411\u2013416.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BF03188779_CR2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(88)92529-9","volume":"ii","author":"Z.R. Chen","year":"1988","unstructured":"Chen Z.R., Somogyi A.A., Bochner F. (1988) Polymorphic O-demethylation of codeine. Lancet, ii, 914\u2013915.","journal-title":"Lancet"},{"key":"BF03188779_CR3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2125.1989.tb03556.x","volume":"28","author":"Q.Y. Yue","year":"1989","unstructured":"Yue Q.Y., Svensson J.O., Alm C, Sj\u00f6qvist F., S\u00e4we J. (1989): Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br. J. Clin. Pharmacol., 28, 639\u2013645.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BF03188779_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/clpt.1990.4","volume":"47","author":"\u00d6. Mortimer","year":"1990","unstructured":"Mortimer \u00d6., Persson K., Ladona M.G., et al. (1990): Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P450IID1. Clin. Pharmacol. Ther., 47, 27\u201335.","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF03188779_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00280101","volume":"41","author":"J. Desmeules","year":"1991","unstructured":"Desmeules J., Gascon M.P., Dayer P., Magistris P. (1991): Impact of environmental and genetic factors on codeine analgesia. Eur. J. Clin. Pharmacol., 41, 23\u201326.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF03188779_CR6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/BF00615971","volume":"29","author":"T. Leemann","year":"1986","unstructured":"Leemann T., Dayer P., Meyer U.A. (1986): Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur. J. Clin. Pharmacol., 29, 739\u2013741.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF03188779_CR7","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/0006-2952(87)90573-9","volume":"36","author":"P. Dayer","year":"1987","unstructured":"Dayer P., Kronbach T., Eichelbaum M., Meyer U.A. (1987): Enzymatic basis of the debrisoquine\/sparteine type genetic polymorphism of drug oxidation \u2014 Characterisation of bufuralol l\u2019-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic defiency. Biochem. Pharmacol., 36, 4145\u20134152.","journal-title":"Biochem. Pharmacol."},{"key":"BF03188779_CR8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/clpt.1989.6","volume":"45","author":"P. Dayer","year":"1989","unstructured":"Dayer P., Leemann T., Stribemi R. (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450 dbl activity. Clin. Pharmacol. Ther., 45, 34\u201340.","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF03188779_CR9","volume-title":"Technical Report of the Division of Clinical Pharmacology","author":"L.B. Sheiner","year":"1983","unstructured":"Sheiner L.B. (1983): ELSFIT, a program for the extended least squares fit to individual pharmacokinetic data. In: Technical Report of the Division of Clinical Pharmacology. University of California, San Francisco, CA, USA"},{"key":"BF03188779_CR10","volume-title":"Statistical methods","author":"G.W. Snedecor","year":"1980","unstructured":"Snedecor G.W., Cochran W.G. (1980): Statistical methods. 7th edn. Iowa State University Press, Ames.","edition":"7th edn."},{"key":"BF03188779_CR11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1042\/bj0550170","volume":"55","author":"M. Dixon","year":"1953","unstructured":"Dixon M. (1953): The determination of enzyme inhibitor constants. Biochem. J., 55, 170\u2013171.","journal-title":"Biochem. J."},{"key":"BF03188779_CR12","first-page":"59","volume-title":"International Encyclopedia of Pharmacology and Therapeutics, Section 6, Clinical Pharmacolgy, vol. 1.","author":"R.W. Houde","year":"1966","unstructured":"Houde R.W., Wallenstein S.L., Beawer W.T. (1966): Evaluation of analgesics in patients with cancer pain. In: Lasagna L. ed. International Encyclopedia of Pharmacology and Therapeutics, Section 6, Clinical Pharmacolgy, vol. 1. Oxford: Pergamon Press, pp 59\u201397."},{"key":"BF03188779_CR13","first-page":"822","volume":"41","author":"T. Kronbach","year":"1985","unstructured":"Kronbach T., Dayer P., Meyer U.A. (1985): Debrisoquine\/ sparteine-type polymorphism in drug oxidation: a model of the active site of the involved cytochrome P450 isozyme. Experientia, 41, 822.","journal-title":"Experientia"},{"key":"BF03188779_CR14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/00498258609050251","volume":"16","author":"U.A. Meyer","year":"1986","unstructured":"Meyer U.A., Gut J., Kronbach T., et al. (1986): The molecular mechanisms of two common polymorphisms of drug oxidation \u2014 Evidence for functional changes in cytochrome P450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica, 16, 449\u2013464.","journal-title":"Xenobiotica"},{"key":"BF03188779_CR15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1399-6576.1982.tb01845.x","volume":"74","author":"J. S\u00e4we","year":"1982","unstructured":"S\u00e4we J., Pacifici G.M., Kager L., Von Bahr C. and Rane A. (1982): Glucuronidation of morphine in human liver and interaction with oxazepam. Acta Anaesth. Scand., 74 (Suppl.), 47\u201351.","journal-title":"Acta Anaesth. Scand."},{"key":"BF03188779_CR16","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/0006-2952(85)90533-7","volume":"34","author":"G. Bahr Von","year":"1985","unstructured":"Von Bahr G., Spina E., Birgersson G., et al. (1985): Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol., 34, 2051\u20132055.","journal-title":"Biochem. Pharmacol."},{"key":"BF03188779_CR17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00613523","volume":"31","author":"A.E. Balant-Gorgia","year":"1986","unstructured":"Balant-Gorgia A.E., Balant L.P., Genet Ch., Dayer P., Aeschlimann J.M., Garrone G. (1986): Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur. J. Clin. Pharmacol., 31, 449\u2013455.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF03188779_CR18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2125.1990.tb03639.x","volume":"29","author":"M. Due Nielsen","year":"1990","unstructured":"Due Nielsen M., Br\u00f6sen K., Gram L.F. (1990): A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br. J. Clin. Pharmacol., 29, 299\u2013304.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BF03188779_CR19","first-page":"33","volume-title":"European cooperation in the field of scientific and technical research \u2014 European consensus conference on pharmacogenetics","author":"P. Dayer","year":"1990","unstructured":"Dayer P. (1990): Advantages and drawbacks of probe drugs for the assessment of phenotypic expression of cytochrome P450dbI (P450IID6). In: Alvan G., Balant L.P., Bechtel P.R., Boobis A.R., Gram L.F., Pithan K. eds. European cooperation in the field of scientific and technical research \u2014 European consensus conference on pharmacogenetics. Luxemburg, Commission of the European Communities, pp 33\u201342."},{"key":"BF03188779_CR20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/331442a0","volume":"331","author":"F.J. Gonzalez","year":"1988","unstructured":"Gonzalez F.J., Skoda R.C., Kimura S., et al. (1988); Characterization of the common genetic defect in humans deficient in debrisoquin metabolism. Nature, 331, 442\u2013446.","journal-title":"Nature"},{"key":"BF03188779_CR21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/dna.1988.7.79","volume":"7","author":"FJ. Gonzalez","year":"1988","unstructured":"Gonzalez FJ., Schmid B.J., Umeno M., et al. (1988): Human P450PCN1 sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7, 79\u201386.","journal-title":"DNA"},{"key":"BF03188779_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0026-895X(25)11259-5","volume":"35","author":"T. Yasumori","year":"1989","unstructured":"Yasumori T., Murayama N., Yamozoe Y., et al. (1989): Expression of a human P450IIC gene in yeast cells using galactose-inductible expression system. Mol. Pharmacol., 35, 443\u2013449.","journal-title":"Mol. Pharmacol."},{"key":"BF03188779_CR23","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/bi00438a014","volume":"28","author":"W.R. Brian","year":"1989","unstructured":"Brian W.R., Srivastava P.D., Umbenhauer D.R., Lloyd R.S., Guengerich F.P. (1989): Expression of a human liver cytochrome P450 protein with tolbutamide hydroxylase activity inSaccharomyces cerevisiae. Biochemistry, 28, 4993\u20134999.","journal-title":"Biochemistry"},{"key":"BF03188779_CR24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF00637732","volume":"36","author":"K. Br\u00f6sen","year":"1989","unstructured":"Br\u00f6sen K., Gram L.F. (1989): Clinical significance of the sparteine\/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol., 36, 537\u2013547.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF03188779_CR25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2165\/00003088-199018030-00004","volume":"18","author":"K. Br\u00f6sen","year":"1990","unstructured":"Br\u00f6sen K. (1990): Recent developments in hepatic drug oxidation \u2014 Implications for clinical pharmacokinetics. Clin. Pharmacokinet., 18, 220\u2013239.","journal-title":"Clin. Pharmacokinet."},{"key":"BF03188779_CR26","first-page":"377","volume":"46","author":"M. Eichelbaum","year":"1990","unstructured":"Eichelbaum M., Gross A.S. (1990): The genetic polymorphism of debrisoquine\/sparteine metabolism \u2014 Clinical aspects. Clin. Pharmacol. Ther., 46, 377\u2013394.","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03188779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03188779\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03188779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T22:07:18Z","timestamp":1740348438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03188779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,4]]}},"alternative-id":["BF03188779"],"URL":"https:\/\/doi.org\/10.1007\/bf03188779","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[1992,4]]}}}